Ataxion

About Ataxion

Ataxion Therapeutics operated as a discovery-stage biopharmaceutical company with a sharp focus on developing novel small-molecule therapeutics for neurological diseases. The company was established in April 2013, originating from the Atlas Venture seed program. It was co-founded by Dr. Joshua Resnick, who also served as CEO, and Dr. David Grayzel, who was the Managing Director at Atlas Venture Development Corporation. Both founders brought significant experience to the venture, with Dr. Resnick also being a Venture Partner at Atlas Venture, deeply embedding the company within a framework of venture-backed life science development.

The company's primary mission was to address hereditary ataxias, a group of orphan genetic disorders characterized by the degeneration of the cerebellum, which is the brain's coordination center. This condition leads to severe difficulties with walking, speech, and daily activities. The core of Ataxion's strategy was based on developing ion-channel modulators. A key milestone occurred in July 2013 when Ataxion acquired an ataxia program from the Danish biotechnology firm Aniona (later renamed Saniona), a specialist in ion-channel drug discovery. This acquisition formed the foundation of Ataxion's therapeutic pipeline, with Saniona continuing to handle program discovery activities. The potential application for these drugs was envisioned to extend beyond hereditary ataxias to other degenerative neurological disorders like Multiple Sclerosis and Huntington's Disease.

Financially, Ataxion secured significant backing to advance its research. In March 2014, the company announced $17 million in Series A financing from Atlas Venture and Biogen Idec. This funding was structured with Biogen Idec also providing non-dilutive R&D support and holding an option to acquire Ataxion at pre-negotiated terms after the completion of a Phase 1 study. The total raised in this round eventually reached $34 million. The company's journey as an independent entity concluded in March 2017 when it was acquired by and merged into Cadent Therapeutics (formerly Luc Therapeutics), a company focused on precision medicine for neurological and psychiatric diseases.